Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Other Operating Expenses (2016 - 2025)

Tg Therapeutics has reported Other Operating Expenses over the past 10 years, most recently at $38.1 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $38.1 million for Q4 2025, up 147.69% from a year ago — trailing twelve months through Dec 2025 was $100.7 million (up 161.7% YoY), and the annual figure for FY2025 was $100.7 million, up 161.69%.
  • Other Operating Expenses for Q4 2025 was $38.1 million at Tg Therapeutics, up from $28.1 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for TGTX hit a ceiling of $38.1 million in Q4 2025 and a floor of $2000.0 in Q3 2022.
  • Median Other Operating Expenses over the past 5 years was $2.7 million (2023), compared with a mean of $7.7 million.
  • Biggest five-year swings in Other Operating Expenses: tumbled 99.32% in 2022 and later skyrocketed 261700.0% in 2023.
  • Tg Therapeutics' Other Operating Expenses stood at $210000.0 in 2021, then tumbled by 98.57% to $3000.0 in 2022, then skyrocketed by 261700.0% to $7.9 million in 2023, then skyrocketed by 96.07% to $15.4 million in 2024, then skyrocketed by 147.69% to $38.1 million in 2025.
  • The last three reported values for Other Operating Expenses were $38.1 million (Q4 2025), $28.1 million (Q3 2025), and $18.9 million (Q2 2025) per Business Quant data.